KP
REGN icon

Keel Point’s Regeneron Pharmaceuticals REGN Stock Holding History

Keel Point’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$297K Sell
385
-158
-29% -$121K 0.02% 357
2025
Q4 		$419K Buy
543
+96
+21% +$65.2K 0.03% 336
2025
Q3 		$251K Buy
+447
New +$253K 0.02% 451
2025
Q2 		– Sell
-368
Closed -$233K – 527
2025
Q1 		$233K Sell
368
-38
-9% -$26.1K 0.02% 406
2024
Q4 		$289K Sell
406
-186
-31% -$156K 0.02% 332
2024
Q3 		$622K Hold
592
– – 0.05% 202
2024
Q2 		$686K Buy
592
+152
+35% +$147K 0.06% 182
2024
Q1 		$423K Buy
440
+172
+64% +$164K 0.04% 230
2023
Q4 		$235K Buy
268
+4
+2% +$3.29K 0.03% 298
2023
Q3 		$217K Buy
+264
New +$207K 0.03% 287

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Keel Point's REGN Position: Q1 2026 in Review

Keel Point reduced its Regeneron Pharmaceuticals (REGN) stake by 29% in Q1 2026, selling an estimated $121K and leaving 385 shares worth $297K. The position accounts for 0.02% of the portfolio, ranked #357.

Keel Point first reported a position in REGN in Q3 2023 and has held it in 10 quarters since. The position peaked at $686K in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Keel Point held 385 shares of Regeneron Pharmaceuticals worth $297K as of Q1 2026.
  • Keel Point sold 158 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $121K.
  • Regeneron Pharmaceuticals made up 0.02% of Keel Point's portfolio in Q1 2026, its #357 holding.
  • Keel Point first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Keel Point's Regeneron Pharmaceuticals position peaked at $686K in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.